Trials / Sponsors / Timothy Voorhees
Timothy Voorhees
Academic / Other · 3 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Phase 1 | 2025-06-16 |
| Recruiting | Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | 2023-03-23 |
| Completed | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive N Non-Hodgkin Lymphoma | Phase 1 | 2023-01-31 |